CJC-1295 DAC

CJC-1295 with DAC (Drug Affinity Complex) is a synthetic analogue of growth hormone-releasing hormone (GHRH) engineered for dramatically extended duration of action. While the peptide backbone is derived from the first 29 amino acids of native GHRH (1-29) with several amino acid substitutions to improve stability and receptor binding, the defining feature is the DAC technology: a maleimidopropionic acid (MPA) chemical moiety appended to the peptide that reacts with cysteine-34 on endogenous albumin after injection, forming a covalent amide bond.

This albumin conjugation strategy effectively converts CJC-1295 into a long-lasting depot within the bloodstream itself. Native albumin has a half-life of approximately 19 days; by covalently attaching to albumin, CJC-1295 DAC achieves a biological half-life of 6-8 days. A single subcutaneous injection results in sustained, continuous GHRH receptor stimulation throughout the week - a pharmacokinetic profile that no other GHRH analogue achieves.

The consequence of this sustained GHRH receptor activation is a persistent elevation of growth hormone secretion and, downstream, IGF-1 production. Research data suggests CJC-1295 DAC can raise mean IGF-1 levels by 200-400% above baseline and maintain this elevation for 28 days or more after a single injection, with the 200% elevation persisting well into the week post-injection. This is in stark contrast to shorter-acting GHRH analogues like Sermorelin or Mod GRF(1-29), which produce brief GH pulses lasting 2-3 hours.

The pharmacological distinction between pulse-based and continuous GH stimulation has significant implications for research. Endogenous GH is naturally secreted in pulses (primarily during sleep), and some researchers argue this pulsatility is physiologically important. Continuous GHRH stimulation from CJC-1295 DAC shifts the GH secretion pattern from pulsatile toward tonic - a fundamentally different physiological state. This makes CJC-1295 DAC particularly interesting as a research tool for studying the differential effects of pulsatile versus continuous GH signaling on body composition, metabolism, and organ function.

The body composition effects documented in research protocols are substantial. The combination of sustained IGF-1 elevation and continuous mild GH stimulation supports protein synthesis, fat oxidation, and connective tissue maintenance in a way that mimics the biological state of youthful GH secretion. Researchers studying age-related changes in body composition, sarcopenia, and metabolic health have found CJC-1295 DAC to be a valuable tool for recreating robust GH axis activity in subjects with diminished endogenous secretion.

CJC-1295 DAC is commonly combined with ghrelin mimetics such as Ipamorelin, GHRP-2, or GHRP-6 in research protocols. While the DAC version provides continuous background GHRH stimulation, the co-administration of a GHRP peptide creates an amplified GH pulse at the time of injection - combining both the pulsatile and tonic components of GH secretion and producing the most robust overall GH stimulation achievable with synthetic peptides.